
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
1093 | Hong Kong | HKD | Delayed | |
CHJTF | OTC Markets | USD | Delayed | |
1093 | Frankfurt | EUR | Delayed | |
1093 | TradeGate | EUR | Delayed |
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People’s Republic of China.
Name | Age | Since | Title |
---|---|---|---|
Chun Kwok Au | 52 | 2021 | Independent Non-Executive Director |
Hongguang Wang | 62 | 2021 | Independent Non-Executive Director |
Quan Li | 45 | 2022 | Independent Non-Executive Director |
Bing Yao | 48 | 2024 | Executive Director |
Xin Cai | 33 | 2024 | Group Executive President, President of the Group’s Marketing Strategy Division & Executive Director |
Zhenguo Wang | 55 | 2012 | Executive Director |
Weidong Pan | 56 | 2006 | Executive Director |
Huaiyu Wang | 62 | 2010 | Executive Director |
Chuan Chen | 61 | 2016 | Independent Non-Executive Director |
Chunlei Li | 49 | 2017 | Executive Director & Chief Scientist |
Cheuk Kin Law | 63 | 2021 | Independent Non-Executive Director |
Weiping Chen | 45 | 2024 | Executive Director |
Dongchen Cai | 71 | 1997 | Executive Chairman |
Bo Wang | 65 | 2012 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review